TGF‐β antagonist attenuates fibrosis but not luminal narrowing in experimental tracheal stenosis
Open Access
- 16 November 2016
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 127 (3) , 561-567
Abstract
Objective: Acquired tracheal stenosis (ATS) is an unusual disease often secondary to prolonged mechanical trauma. Acquired tracheal stenosis pathogenesis involves inflammation and subsequent fibrosis with narrowing of the tracheal lumen. Transforming growth factor‐β1 (TGF‐β) represents a pivotal factor in most fibrotic processes, and therefore a potential target in this context. The aim of this study is to analyze the role of TGF‐β as a target for anti‐fibrotic interventions in tracheal stenosis.Methods: Human stenotic tracheobronchial tissues from patients with benign airway stenosis and normal controls from pneumonectomy specimens were analyzed. Tracheal stenosis was induced in adult NZ rabbits by a circumferential thermal injury to the mucosa during open surgery and re‐anastomosis. Rabbits were treated postoperatively with a peritracheal collagen sponge containing a TGF‐β peptide antagonist (p17) or vehicle. Fibrosis was determined by Masson's trichrome staining, and smooth muscle cell α‐actin+ (α‐SMA+ Confirm accuracy.) myofibroblasts, connective tissue growth factor (CTGF), and p‐Smad2/3 expression by immunohistochemistry.Results: Human and rabbit stenotic tissues showed extensive submucosal fibrosis, characterized by significantly increased α‐SMA+ myofibroblasts and CTGF expression. In human stenotic lesions, increased p‐Smad2/3+ nuclei were also observed. p17 treatment significantly reduced the fibrotic thickness, as well as the density of α‐SMA+ myofibroblasts and CTGF+ cells in rabbit stenotic lesions, but failed to improve the luminal area.Conclusion: ATS is characterized by a TGF‐β dependent fibrotic process, but reduction of the fibrotic component by TGF‐β1 antagonist therapy was not sufficient to improve tracheal narrowing, suggesting that fibrosis may not be the main contributor to luminal stenosis.Level of Evidence: NA. Laryngoscope, 127:561–567, 2017Keywords
Funding Information
- Fondo de Investigación Sanitaria, Instituto de Salud Carlos III (FIS PI12/00646, PI12/439)
- FEDER (European Regional Development Fund)
This publication has 39 references indexed in Scilit:
- Transforming Growth Factor-Beta Inhibition Reduces Progression of Early Choroidal Neovascularization Lesions in Rats: P17 and P144 PeptidesPLOS ONE, 2013
- Blocking TGF-β1 Protects the Peritoneal Membrane from Dialysate-Induced DamageJournal of the American Society of Nephrology, 2011
- Therapeutic effect of a peptide inhibitor of TGF-β on pulmonary fibrosisCytokine, 2011
- The role of airway stenting in pediatric tracheobronchial obstruction☆European Journal of Cardio-Thoracic Surgery, 2008
- Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide libraryCytokine, 2007
- Rabbit Model of Airway Stenosis Induced by Scraping of the Tracheal MucosaThe Laryngoscope, 2005
- Perspective Article: Tissue repair, contraction, and the myofibroblastWound Repair and Regeneration, 2005
- Anastomotic complications after tracheal resection: Prognostic factors and managementThe Journal of Thoracic and Cardiovascular Surgery, 2004
- A synthetic peptide from transforming growth factor β type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injuryCytokine, 2003
- Improved canine model for laryngotracheal stenosis☆☆☆★★★Otolaryngology–Head and Neck Surgery, 2000